Register now!
Login
OCTOBER 11-12, 2024
Fondazione Cariplo - Conference Center
MILAN, ITALY
Poster Exhibition
View and download the Posters, divided by topic, presented at...
Diagnosis, staging, HCC risk and Antiviral Therapy
Nearly One-Third of Veterans with Hepatitis Delta Virus Infection in the United States Have Already Developed Cir- rhosis or Hepatocellular Carcinoma at Time of Diagnosis
R.J. Wong, Z. Yang, J. Lim, J.H. Jou, R. Cheung
Quantification of plasma HDV RNA in untreated and bulevirtide-treated patients with CHD: a comparison between robogene 2.0, Eurobioplex and altostar
M.P. Anolli, S. Uceda Renteria, E. Degasperi, F. Facchetti, D. Sambarino, M. Borghi, R. Perbellini, R. Soffredini, S. Monico, A. Callegaro, P. Lampertico
Value and kinetics of virological markers in the natural course of chronic hepatitis D virus infection
L. Sandmann, V. Ohlendorf, A. Ehrenbauer, B. Bremer, A.R.M. Kraft, M. Cornberg, K. Deterding, H. Wedemeyer, B. Maasoumy
Hepatitis delta virus (HDV) replication through HBV integrants in HCC recurrence after liver transplantation
L. Di Marco, N. De Maria, A. Pivetti, A. Colecchia, A. Romanzi, A. Spallanzani, G. Guaraldi, G. Dolci, G. Ciusa, F. Di Benedetto, P. Magistri, S. Di Sandro, E. Degasperi, M.P. Anolli, P. Lampertico, D. Giosa, D. Lombardo, G. Raimondo, T. Pollicino
Development and implementation of an hepatitis D detection and linkage to care program in Catalonia. Preliminary results.
A. Palom, A. Rando-Segura, L. Calatayud Samper, G. Fernandez Rivas, A. Sellés Sanchez, S. Mormeneo Bayo, D. Pérez del Campo, M.M.O. Perez Moreno, J. Ayats, D. Tabernero, J. Castellote, R.M. Morillas, J.C. Quer, C. Aracil Blanch, C. Lopez, D. Salazar, A. Marco, M. Buti
THE WHO HDV RNA International Standard does not reflect variability of real-world samples
B. Bremer, K. Deterding, K. Port, B. Gey, C. Früchtel, A. Reinhardt, I. Lachmann, M. Cornberg, H. Kefalakes, B. Maasoumy, H. Wedemeyer, L. Sandmann
Bulevirtide: a success case after pegINFα failure
A. Carraro, R. Marocco, B. Kertusha, G. Mancarella, L. Ansaldo, L. Fondaco, S. De Maria, S. Corazza, A. Gasperin, A.Grimaldi, C. Del Borgo, M. Lichtner
The prevalence and characteristics of hepatitis B/D in 48,522 HBsAg tested individuals in Mongolia
G. Jargalsaikhan and H. Kamal, S.n Enkhtaivan, D. Bruce, B. Dashtseren, T. Ulziibadrakh, M. Batkhuu, P. Bat-Ulzii, S. Byambabaatar, N. Dashdorj and S. Aleman
Validation of Streamlined serodiagnosis of hepatitis delta virus
A. Dashdorj, K. An, N. Ariungerel, S. Han, G. Choi, S. Ah Kim, T.H. Kim, M. Chung, O. Oidosambuu, B. Ochirsum, S. Enkhtaivan, S. Enkhjargal, P. Bat-Ulzii, E. Ochirbat, N. Dashdorj, N. Dashdorj, N.J. Cho
Limited use of established risk scores for the prediction of hepatocellular carcinoma in patients with chronic hepatitis D virus infection
R. Iker, A. Wranke, H. Schneider, H. Wedemeyer, H. Kefalakes, L. Sandmann
Is there a Hepatitis Delta Virus variant in West Africa, not detected by current serological diagnostic tests?
P. Hamouda, A. Gerber, A. Ramirez Mena, V. Delagarde, B. Wembulua Shinga, M. Seydi, N. Fatou Ngom, O. Ndiaye, E. Gordien, S. Brichler, G. Wandeler, F. Le Gal
Novel anti-HDV therapies require reliable quantification of plasma HDV RNA: A European multicenter study
A. Reinhardt, E. Stelzl, J. Kress, A. Olivero, P. Lampertico, A. Heim, S. Aberle, H. Wedemeyer, A. Berger, B. Gey, C. Früchtel, H.H. Kessler
The asymmetry of the liver and spleen stiffness measures between patients with chronic hepatitis B and D reflects important clinic-pathologic differences
F. Damone, P. Colombatto, A. Pinna, G. Ricco, D. Cavallone, G. Petralli, L. De Stefano, B. Coco, L. Surace, V. Romagnoli, F. Oliveri, F. Bonino and M. R. Brunetto
Diagnostic performances of different HDV RNA quantification assays used in clinical practice in Italy: results from a national quality control multicenter study
L. Piermatteo, R. Salpini, G.P. Caviglia, A. Bertoli, M.R. Brunetto, B. Bruzzone, A. Callegaro, C. Caudai, D. Cavallone, L. Chessa, F. Coghe, N. Coppola, N. Cuomo, S. D’Anna, M. Di Stefano, L. Duca, F. Facchetti, C. Farina, D. Ferraro, E. Franchin, D. Francisci, S. Galli, A.R. Garbuglia, W. Gennari, V. Ghisetti, P. Lampertico, N. Marascio, S. Menzo, V. Micheli, G. Niro, A. Olivero, P. Paba, C.I. Palermo, O. Palmieri, S. Paolucci, M. Pisaturo, T. Pollicino, G. Raffa, G. Torre, O. Turriziani, S. Uzzau, M. Vatteroni, M. Zazzi, A. Craxì, F. Ceccherini-Silberstein, V. Svicher on behalf of the Virology Italian Network Vironet C
Hepatitis Delta Virus RNA quantification: a story about fruitful collaboration between private company and academic laboratory
A. Gerber, M. Breuer, V. Delagarde, K. Rottengatter, S. Dziri, E. Vincent, E. Gordien, F. Le Gal, S. Brichler
Clinical evaluation of the Altostar HDV RT-PCR Kit 1.5
J.C. Eichholz, B. Bremer, H. Wedemeyer, B. Maasoumy, L. Sandmann
Hepatitis Delta infection in individuals living with HIV - multicentric portuguese study
C. Valente, R. Carvalho, R. Lino, D. Alves, R. Aleixo, C. Antunes, M. Ferreira, C. Pineiro, P. Vasques, I. Casella, C. Azevedo, R. Serrão, A.C. Miranda, K. Mansinho, T. Teixeira
HDV RNA assay sensitivity is critical for determining a correct outcome during Bulevirtide antiviral therapy
I. Carey, M. Anderson, Z. Cargill, S. Shah, J. Lok, G. Cloherty, G. Dusheiko, K. Agarwal
Treatment with pegIFNα inhibits cell division-mediated spread of HDV in a humanized mouse model supporting cell proliferation
T. Volz, A. Volmari, L. Allweiss, M. Luetgehetmann, S.P. Fletcher, M.M. Holdorf, R.C. Muench, M. Dandri
Chronic delta hepatitis without efficient treatment poses a greater risk for hepatocellular cancer development than chronic hepatitis B with efficient treatment
O. Keskin, C. Kalkan, M. Gumussoy, E. Yurdcu, Z. Melekoglu Ellik, Y. Yilmaz, H. Sahin, B. Ozturk, Y. Emre Parlar, R. Idilman, M. Bozdayi, C. Yurdaydin
Complexities of Hepatitis Delta Virus Testing in a High HBV Prevalence Setting in London
N. Kokkinos, T. Kandaswamy Murugesan, A. Millar, G. Kerry, K.N. Wai-Mon, E. Nastouli, A.M. Geretti
High frequency of liver cirrhosis in European patients with hepatitis D: Data from a large multicentre study (D-SOLVE and HDV-1000 consortia)
A. Wranke, H. Kamal, Z. Cargill, M. Radu, E. Degasperi, K. Lindahl, P. Dörge, J. Kahlhöfer, K. Agarwal, P. Lampertico, F.A. Caruntu, H. Wedemeyer, S. Aleman, I. Carey, L. Sandmann
Current and new Antiviral Treatments
Bulevirtide for patients with chronic hepatitis D (CHD) in Italy: a multicenter prospective nationwide real-life study (D-SHIELD)
M.P. Anolli, E. Degasperi, G. D’Offizi, A. Rianda, A. Loglio, M. Viganò, A. Ciancio, Y. Troshina, M.R. Brunetto, B. Coco, S. Zaltron, M. Milella, P. Toniutto, L. Marinaro, A. Gori, A. Federico, T.A. Santantonio, G. Verucchi, F. Morisco, A. Mangia, S. De Nicola, M. Maracci, A. Romano, P. Gatti, R. Zampino, M. Persico, P. Pozzoni, A. Pellicelli, N. Coppola, F. Pileri, M. Tonnini, M. Puoti, P. Lampertico
Virological and clinical outcomes of patients with HDV-related cirrhosis treated with bulevirtide monotherapy for up to 96 weeks: a multicenter european study (SAVE-D)
E. Degasperi, M.P. Anolli, M. Jachs, T. Reiberger, V. De Ledinghen, S. Metivier, G. D’Offizi, F. di Maria, C. Schramm, H. Schmidt, C. Zöllner, F. Tacke, C. Dietz-Fricke, H. Wedemeyer, M. Papatheodoridi, G. Papatheodoridis, I. Carey, K. Agarwal, F. Van Bömmel, M.R. Brunetto, M. Cardoso, G. Verucchi, A. Ciancio, F. Zoulim, S. Aleman, N. Semmo, A. Mangia, M.N. Hilleret, U. Merle, T.A. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D’Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, D. Roulot, M. Viganò, A. Loglio, A. Federico, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, M. Puoti, P. Lampertico
Bulevirtide monotherapy prevents liver decompensation in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
E. Degasperi, A. De Silvestri, M.P. Anolli, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, R. Soffredini, S. Monico, V. De Ledinghen, S. Metivier, M. Jachs, T. Reiberger, G. D’Offizi, C. Dietz-Fricke, G. Papatheodoridis, M.R. Brunetto, G. Verucchi, A. Ciancio, F. Zoulim, A. Mangia, M.N. Hilleret, T.A. Santantonio, N. Coppola, A. Pellicelli, B. Roche, X. Causse, L. D’Alteroche, J. Dumortier, N. Ganne, F. Heluwaert, I. Ollivier, A. Loglio, A. Federico, F. Pileri, M. Maracci, M. Tonnini, J.P. Arpurt, K. Barange, E. Billaud, S. Pol, A. Gervais, A. Minello, I. Rosa, M. Puoti, P. Lampertico
Continued Treatment of Early Virologic Non-responders or Partial Responders With Bulevirtide Monotherapy for Chronic Hepatitis Delta Leads to Improvement in Virologic and Biochemical Responses. Results From an Integrated Analysis at Week 96
P. Lampertico, H. Wedemeyer, M.R. Brunetto, P. Bogomolov, T. Stepanova, M. Bourlière, H. Fontaine, G. M. Chee, D. Manuilov, Q. An, A. H. Lau, B. L. Da, J. F. Flaherty, R. C. Mercier, C. Frenette, A. Osinusi, G. Sebastian Gherlan, A. Streinu-Cercel, S. Zeuzem, M. Cornberg, D. Roulot, F. Zoulim, S. Aleman, and T. Asselah
Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg Monotherapy From the Ongoing Phase 3 Study MYR301
P. Lampertico, S. Aleman, M. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, M. Viacheslav, O. Sagalova, T. Stepanova, G.M. Chee, D. Manuilov, M. Li, A.H. Lau, A. Osinusi, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, H. Wedemeyer
Forty-Eight-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Patients With Chronic Hepatitis Delta: Final Results From the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204
T. Asselah, V. Chulanov, P. Lampertico, H. Wedemeyer, A. Streinu-Cerce, V. Pantea, S. Lazar, G. Sebastian Gherlan, P. Bogomolov, T. Stepanova, V. Morozov, V. Syutkin, O. Sagalova, D. Manuilov, R.C. Mercier, L. Ye, G.M. Chee, B.L. Da, A.H. Lau, A. Osinusi, M. Bourlière, V. Ratziu, S. Pol, M.N. Hilleret and F. Zoulim
Treatment of chronic hepatitis D with bulevirtide: 1st year report
R. Rapetti, M.G. Crobu, R. Minisini, C. Smirne, P. Ravanini, M. Pirisi
Bulevirtide monotherapy in patients with compensated cirrhosis and CSPH: a 96-week interim kinetic analysis of real-life setting
O. Wasserman, L. Shekhtman, S.J. Cotler, E. Degasperi, M.P. Anolli, S. Colonia Uceda Renteria, D. Sambarino, M. Borghi, R. Perbellini, F. Facchetti, F. Ceriotti, H. Dahari, P. Lampertico
Improvement in Liver Histology Is Observed in Most Patients With Chronic Hepatitis Delta After 48 Weeks of Bulevirtide Monotherapy
P. Lampertico, S. Aleman, P. Bogomolov, T. Stepanova, M. Cornberg, S. Ciesek, A. Berger, D. Manuilov, M. Li, A.H. Lau, B.L. Da, G.M. Chee, M.R. Brunetto, S. Zeuzem, H. Wedemeyer
Rapid reductions of HDV RNA and ALT with the monoclonal antibody, BJT-778: results from a phase 2 study
K. Agarwal, M. Dobryanska, A. Jucov, P. Kennedy, E.J. Gane, M.F. Yuen, G. Lai-Hung Wong, S. Strasser, J. Holmes, S. Roberts, H. Javanbakht, J. Stanton, N. Shulman
Treatment of chronic hepatitis delta with bulevirtide in Portugal: data from a real-life cohort
M.F. Cardoso, F. Calinas, C. Fonseca, C. Gouveia, A.A. Horta, A. M. Vieira, M. Machado, C. Palmela, J. Branco, G. Alexandrino, A. Martins
Detection and characterization of anti-preS1 antibodies in HDV-infected patients under Bulevirtide treatment
Y. Aronthippaitoon, N. Szerman, E. Roch, F. Zoulim, C. Sureau, C. Gaudy-Graffin, and the ANRS HDEP01 Buldelta study group2
Treatment of HDV infection in Solid Organ Transplant with Bulevirtide: a case report
B. Pinchera, A. d’Agostino, E. Trucillo, F. Cuccurullo, A.R. Buonomo, I. Gentile
Patient-Reported Outcomes Among Patients With Chronic Hepatitis Delta Treated With Bulevirtide 2 mg: A LongTerm Analysis of the Phase 3 MYR301 Trial at 96 Weeks
M. Buti, H. Wedemeyer, S. Aleman, V. Chulanov, V. Morozov, O. Sagalova, T. Stepanova, R. G. Gish, A. Lloyd, V. Suri, D. Manuilov, G. M. Chee, A. O. Osinusi, J. F. Flaherty, M. Rock, C. Kim, S. Pandey, B. Singh, and P. Lampertico
Real life experience of HBV/HDV-related compensated cirrhosis treatment in an Italian prison. A case report.
G. Quartini, C. Di Giuli, A. Lavagna, A. Marozzo, D. Francisci
Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy
F. Zoulim, V. Chulanov, P. Lampertico, H. Wedemeyer, A. Streinu-Cercel, V. Pantea, S. Lazar, G.S. Gherlan, P. Bogomolov, T. Stepanova, V. Morozov, V. Syutkin, O. Sagalova, D. Manuilov, R.C. Mercier, L. Ye, G.M. Chee, B.L. Da, A.H. Lau, A. Osinusi, M. Bourlière, V. Ratziu, S. Pol, M.N. Hilleret, T. Asselah
Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta
F. Zoulim, T. Asselah, V. Chulanov, A. Streinu-Cercel, G.S. Gherlan, P. Bogomolov, T. Stepanova, V. Morozov, O. Sagalova, R.C. Mercier, L. Ye, D. Manuilov, A.H. Lau, G.M. Chee, B.L. Da, M. Bourlière, H. Wedemeyer13, P. Lampertico
High Rates of Adherence to Bulevirtide Monotherapy for Chronic Hepatitis Delta Through 96 Weeks: Results From an Interim Analysis of the Phase 3 Study MYR301
S. Aleman, H. Wedemeyer, M.R. Brunetto, A. Blank, P. Andreone, P. Bogomolov, V. Chulanov, N. Mamonova, N. Geyvandova, V. Morozov, O. Sagalova, T. Stepanova, B.L. Da, D. Manuilov, G.M. Chee, M. Li, A.H. Lau, J. Schulze zur Wiesch, M. Cornberg, S. Zeuzem, P. Lampertico
Improvements in Fibrosis and Necroinflammation With Bulevirtide Combined With Pegylated Interferon for Chronic Hepatitis Delta
D. Roulot, F. Zoulim, V. Chulanov, V. Pantea, S. Lazar, G. Placinta, G.S. Gherlan, P. Bogomolov, T. Stepanova, V. Morozov, V. Syutkin, O. Sagalova, R.C. Mercier, D. Manuilov, L. Ye, D. Tedesco, M. Bourliere, M.N. Hilleret, T. Asselah
Virology and Pathogenesis
HIV-HBV-HDV co-infection. Case presentation.
M.N. Radu, C. Tudoran, R.B. Băloi, F.A. Căruntu
Differential patterns of HBV rna and HBcrAG levels in a large european cross-sectional study of untreated patients with chronic hepatitis delta
E. Degasperi, C. Scholtes, B. Testoni, S. Uceda Renteria, M.P. Anolli, C. Charre, F. Facchetti, M.L. Plissonnier, D. Sambarino, R. Perbellini, S. Monico, A. Callegaro, E. García-Pras, S. Lens, M.F. Cortese, X. Forns, S. Pérez-del-Pulgar, M. Heil, M. Levrero, F. Zoulim, P. Lampertico
HELZ2 is an interferon stimulated gene with antiviral properties against Hepatitis Delta Virus
C. Authier, C. Eber, R. Fouillé, C. Bach, C. Pons, E. Charles, E. Huntzinger, M. Rivoire, G. Passot, M. Michelet, M. Oudot, T.F. Baumert, A. Salvetti, B. Seraphin, D. Durantel, .E. Verrier and J. Lucifora
Hospitalised Adults With Hepatitis Delta Virus Infection Have Higher Risk of Disease Progression Than Those With Hepatitis B Virus Monoinfection in Italy
P. Lampertico, V. Perrone, L. Degli Esposti, M. Leogrande, C. Kim, and M. Rock
Baseline characteristics and risk of liver-related events in hepatitis B and C coinfection with and without hepatitis D infection
L.E. Telep, A.W. Singer, K.M. Kwon, A.E. Stead, A.P. Chokkalingam
TIGIT-expression on natural killer cell subsets correlate with liver inflammation and bulevirtide treatment response in chronic hepatitis D
P.C. Chen, K. Deterding, S.A.Engelskircher, M. Cornberg, A. Kraft, N.K Björkström, N. Woller, and H. Wedemeyer
Adenine Base editing of Hepatitis B surface antigen potently inhibits HDV
A. Kumar, E. Combe, E.M. Smekalova, S. Dejene, C-Y. Chen, L. Mougené, M.G. Martinez, G. Ciaramella, M.S. Packer, B. Testoni, F. Zoulim
Deciphering the cellular response to IFN treatment in HDV-infected cells
C. Eber, R. Fouillé, E. Gerges, T.F. Baumert, D. Durantel, J. Lucifora, E.R. Verrier
Epidemiology and natural history of chronic hepatitis B and D infections in France from 2013 to 2022
T. Asselah, V. Loustaud-Ratti, J.P. Bronowicki, E. Maugain, A. Le Blevec, C. Idelovici-Marchal, C. Lacueille, E. Lambourg, S. Larrieu, C. Colombi
Healthcare Resource Utilisation and Costs Among Terminal, Hospitalised Adults With Hepatitis Delta Virus or Hepatitis B Virus Monoinfection in Italy
P. Lampertico, V. Perrone, L.D. Esposti, M. Leogrande, C. Kim, M. Rock
Rational immunotherapy design for clinical development against HDV using a synthetic DNA-prime and protein-boost strategy
G. Ahlén, L. Frelin, J. Yan, C. Bin Ahn Nordström, P. Cunnah, A. Ricardo, N. Mertens, R. Bethell, and M. Sällberg
Development of a rapid test for HDV-specific T cell characterization in whole blood
N. Le Bert, F. Facchetti, A.T. Tan, M.P. Anolli, S. Hariharaputran, S.K. Hang, E. Degasperi, A. Bertoletti, P. Lampertico
HDV persistence can be independent from the extent of HBV reservoir and can be sustained by HBsAg production mainly derived from HBV-DNA integration
S. D’Anna, L. Piermatteo, G. Brancaccio, E. Teti, A. Di Lorenzo, I. Grossi, G. Torre, V. Malagnino, M. Iannetta, F. Ceccherini-Silberstein, C. Pasquazzi, U. Cillo, A. Vitale, E. Gringeri, M. Magrofuoco, M. Pacenti, L. Baiocchi, S. Francioso, I. Lenci, A. Koffas, A.M. Geretti, M. L. Abate, A. Olivero, G. B. Gaeta, L. Sarmati, M. Rizzetto, U. Gill, P. Kennedy, G. P. Caviglia1, V. Svicher, R. Salpini
Low expression of circulating liver-enriched miRNAs in anti-HDAg patients in absence of active viral replication.
M.F. Cortese, J. Pérez Garreta, B. Pacin Ruiz, A. Palom, D. Tabernero, A. Rando Segura, E. Vargas Accarino, J.C. Ruiz Cobo, M. Riveiro Barciela, M. Buti
Real world patient profile for individuals with hepatitis delta virus infection treated with bulevirtide 2mg in Europe
L.E. Telep, C. Kim, K.M. Kwon
High diversity of the TCR repertoire in hepatitis delta virus patients with undetectable viral RNA
M.F. Cortese, A. Palom, B. Pacín Ruiz, F. Rudilla, E. Enrich Randé, M. Antón Iborra, J.C. Ruiz-Cobo, D. Tabernero, M. Riveiro Barciela, A. Rando-Segura, M.J. Herrero, M. Butí
Dichotomy between HBcrAg and pre-genomic HBV RNA in relation to HDV RNA response in patients with chronic hepatitis delta during bulevirtide treatment
Z. Cargill, M. Andreson, J. Lok, S. Shah, G. Cloherty, G. Dusheiko, K. Agarwal, I. Carey
Plasma pre-S1 HBsAg levels during antiviral therapy with Bulevirtide in chronic hepatitis delta patients – any help in predicting response to therapy?
Z. Cargill, M. Anderson, J. Lok, S. Shah, G. Cloherty, G. Dusheiko, K. Agarwal, I. Carey
HDV co-infection and HCV eradication in persons with HIV (PWH): data from the ICONA cohort
A. Tavelli, R. Rossotti, V. Malagnino, V. Svicher, E Quiros-Roldan, A. Bandera, F.M. Fusco, M. Rivano Capparuccia, G.B. Gaeta, A. Antinori, M. Puoti, A d’Arminio Monforte
Role of intrahepatic HDV reservoir in potentially modulating response to bulevirtide treatment at 24 weeks.
A. Di Lorenzo, S. D’Anna, D. Kontogiannis, C. Sorace, A. Crea, E. Teti, V. Malagnino, L. Piermatteo, I. Grossi, C. Castelli, M. Nezzo, B. Carreri, A.M. Geretti, V. Svicher, R. Salpini, L. Sarmati
